Educational Wellness Information Only
This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.
Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.
ARA-290 vs VIP (Vasoactive Intestinal Peptide)
An educational, source-based comparison of ARA-290 and VIP (Vasoactive Intestinal Peptide) — how each peptide works, what it's researched for, and what to know before going deeper.
Erythropoietin-derived peptide researched for neuropathy and tissue repair.
A synthetic 11-amino-acid peptide derived from the erythropoietin molecule. Research indicates it retains the tissue-protective (non-erythropoietic) effects of EPO via the β-common receptor, without stimulating red blood cell production.
- Small-fiber neuropathy and sarcoidosis
- Diabetic neuropathy
- Ischemia-reperfusion injury
- Autoimmune modulation
- • Investigational; not FDA-approved.
- • Does not raise hematocrit like full EPO molecule.
Neuropeptide researched for immune modulation and lung protection.
A 28-amino-acid neuropeptide with broad immunomodulatory, anti-inflammatory, and bronchodilatory effects. Acts via VPAC1 and VPAC2 receptors to regulate T-cell function, macrophage polarization, and airway smooth muscle tone.
- Acute respiratory distress syndrome (ARDS)
- Chronic inflammatory conditions
- Autoimmune modulation
- Bronchial asthma and COPD
- • Short half-life limits therapeutic utility; analogs in development.
- • Not FDA-approved in native form.
Trial-evidence rating
Educational grade reflecting how many peer-reviewed studies and FDA actions we cite for each peptide. Not a clinical recommendation.
Two cited studies; independent replication needed.
Two cited studies; independent replication needed.
Study-by-study comparison
| Peptide | Study | Source | Year | Summary |
|---|---|---|---|---|
| ARA-290 | ARA-290 in sarcoidosis-associated small-fiber neuropathy | Neurology | 2018 | Improved pain scores and corneal nerve fiber density in sarcoidosis patients. |
| ARA-290 | ARA-290 tissue protective effects | British Journal of Pharmacology | 2015 | Reviewed non-hematopoietic protective mechanisms via the innate repair receptor. |
| VIP (Vasoactive Intestinal Peptide) | VIP in acute respiratory distress syndrome | Critical Care Medicine | 2021 | Demonstrated lung-protective effects in preclinical ARDS models. |
| VIP (Vasoactive Intestinal Peptide) | VIP and immune tolerance | Frontiers in Immunology | 2019 | Reviewed mechanisms of T-regulatory cell induction and immune homeostasis. |
Side-effect & safety grid
- Investigational; not FDA-approved.
- Does not raise hematocrit like full EPO molecule.
- Short half-life limits therapeutic utility; analogs in development.
- Not FDA-approved in native form.
Educational summary of considerations reported in research literature — not a complete list of adverse events. Discuss with a licensed clinician before any use.
ARA-290 vs VIP (Vasoactive Intestinal Peptide) — Key differences
- Class: ARA-290 is classified as Neuropathic · Immune Modulation, while VIP (Vasoactive Intestinal Peptide) is Immune · Respiratory.
- Primary research focus: ARA-290 — small-fiber neuropathy and sarcoidosis; VIP (Vasoactive Intestinal Peptide) — acute respiratory distress syndrome (ards).
- Tag: Neuropathic pain · Immune vs Immune · Respiratory.